Literature DB >> 34754594

Abnormal Findings on "T1WI or DWI or MRCP:" An Effective Boolean Interpretation Model in Discriminating Small Pancreatic Ductal Adenocarcinoma from Control Group.

Hainan Ren1, Naoko Mori1, Minami Hirasawa1, Shin Hamada2, Shunji Mugikura1, Atsushi Masamune2, Kei Takase1.   

Abstract

OBJECTIVES: The objectives of the study was to evaluate the diagnostic performance of findings on T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and magnetic resonance cholangiopancreatography (MRCP) separately and to identify an optimal Boolean interpretation model for discriminating patients with small pancreatic ductal adenocarcinoma (PDAC) from control groups in clinical practice.
MATERIAL AND METHODS: We retrospectively enrolled 30 patients with surgery confirmed small PDAC (≤20 mm) and 302 patients without pancreatic abnormality between April 2008 and February 2020. The presence of masses was evaluated by T1WI, T2WI, and DWI. Abnormality of the main pancreatic duct (MPD) was evaluated by T2WI and MRCP. Multivariate logistic regression analysis was performed to select significant sequences for discriminating the small PDAC and control groups. Boolean operators "OR" or "AND" were used to construct sequence combinations. Diagnostic performances of these sequences and combinations were evaluated by X 2 tests.
RESULTS: The sensitivity of T2WI was lowest (20%) for detecting masses. For evaluating MPD abnormality, sensitivity was higher for MRCP than for T2WI (86.7% vs. 53.3%). Multivariate logistic regression analysis showed that T1WI and DWI for detecting the presence of masses and MRCP for evaluating MPD abnormality were significantly associated with differentiation between the two groups (P = 0.0002, P = 0.0484, and P < 0.0001, respectively). Seven combinations were constructed with T1WI, DWI, and MRCP. The combination of findings on "T1WI or DWI or MRCP" achieved the highest sensitivity of 96.7% and negative predictive value of 99.6%.
CONCLUSION: The combination of findings on "T1WI or DWI or MRCP" might be an optimal interpretation model for discriminating small PDAC from control groups in clinical practice.
© 2021 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science.

Entities:  

Keywords:  Boolean operators; Early diagnosis; Non-contrast magnetic resonance imaging; Pancreatic ductal adenocarcinoma; Screening

Year:  2021        PMID: 34754594      PMCID: PMC8571256          DOI: 10.25259/JCIS_158_2021

Source DB:  PubMed          Journal:  J Clin Imaging Sci        ISSN: 2156-5597


  30 in total

Review 1.  MRI of pancreatic tumors.

Authors:  N L Kelekis; R C Semelka
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

2.  Mass-forming type 1 autoimmune pancreatitis mimicking pancreatic cancer.

Authors:  Sojun Hoshimoto; Koichi Aiura; Motomu Tanaka; Masaya Shito; Toshihiro Kakefuda; Hitoshi Sugiura
Journal:  J Dig Dis       Date:  2016-03       Impact factor: 2.325

3.  Value of unenhanced MRI with diffusion-weighted imaging for detection of primary small (≤20 mm) solid pancreatic tumours and prediction of pancreatic ductal adenocarcinoma.

Authors:  H J Park; K M Jang; K D Song; S H Kim; Y K Kim; M J Cha; S-Y Choi; K Min
Journal:  Clin Radiol       Date:  2017-08-04       Impact factor: 2.350

Review 4.  MRI of the Pancreas.

Authors:  Kate A Harrington; Amita Shukla-Dave; Ramesh Paudyal; Richard K G Do
Journal:  J Magn Reson Imaging       Date:  2020-04-17       Impact factor: 4.813

5.  Imaging features of small (≤ 3 cm) pancreatic solid tumors on gadoxetic-acid-enhanced MR imaging and diffusion-weighted imaging: an initial experience.

Authors:  Kyung Mi Jang; Seong Hyun Kim; Young Kon Kim; Min Jung Park; Mi Hee Lee; Jiyoung Hwang; Hyunchul Rhim
Journal:  Magn Reson Imaging       Date:  2012-04-09       Impact factor: 2.546

Review 6.  Early pancreatic cancer.

Authors:  R Tsuchiya; Y Tajima; S Matsuzaki; S Onizuka; T Kanematsu
Journal:  Pancreatology       Date:  2001       Impact factor: 3.996

7.  Preoperative detection of small pancreatic carcinoma: value of adding diffusion-weighted imaging to conventional MR imaging for improving confidence level.

Authors:  Min Jung Park; Young Kon Kim; Seo-youn Choi; Hyunchul Rhim; Won Jae Lee; Dongil Choi
Journal:  Radiology       Date:  2014-07-04       Impact factor: 11.105

Review 8.  MR imaging techniques for pancreas.

Authors:  Temel Tirkes; Christine O Menias; Kumaresan Sandrasegaran
Journal:  Radiol Clin North Am       Date:  2012-05       Impact factor: 2.303

9.  Detection of small (≤ 2 cm) pancreatic adenocarcinoma and surrounding parenchyma: correlations between enhancement patterns at triphasic MDCT and histologic features.

Authors:  Michele Scialpi; Lucio Cagini; Luisa Pierotti; Francesco De Santis; Teresa Pusiol; Irene Piscioli; Michelle Magli; Alfredo D'Andrea; Luca Brunese; Antonio Rotondo
Journal:  BMC Gastroenterol       Date:  2014-01-21       Impact factor: 3.067

10.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.

Authors:  Marcia Irene Canto; Femme Harinck; Ralph H Hruban; George Johan Offerhaus; Jan-Werner Poley; Ihab Kamel; Yung Nio; Richard S Schulick; Claudio Bassi; Irma Kluijt; Michael J Levy; Amitabh Chak; Paul Fockens; Michael Goggins; Marco Bruno
Journal:  Gut       Date:  2012-11-07       Impact factor: 23.059

View more
  2 in total

Review 1.  American College of Rheumatology and the European League Against Rheumatism classification criteria for IgG4-related disease: an update for radiologists.

Authors:  Hainan Ren; Naoko Mori; Satoko Sato; Shunji Mugikura; Atsushi Masamune; Kei Takase
Journal:  Jpn J Radiol       Date:  2022-04-27       Impact factor: 2.701

2.  Letter to the editor on "High signal intensity on diffusion-weighted magnetic resonance images is a useful finding for detecting early-stage pancreatic cancer".

Authors:  Hainan Ren; Naoko Mori; Shunji Mugikura; Kei Takase
Journal:  Abdom Radiol (NY)       Date:  2021-11-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.